Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Vanda Pharmaceuticals stock | 13.19

Own Vanda Pharmaceuticals stock in just a few minutes.

Posted

Fact checked

Vanda Pharmaceuticals Inc is a biotechnology business based in the US. Vanda Pharmaceuticals shares (VNDA) are listed on the NASDAQ and all prices are listed in US Dollars. Vanda Pharmaceuticals employs 284 staff and has a trailing 12-month revenue of around USD$240.6 million.

How to buy shares in Vanda Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Vanda Pharmaceuticals. Find the stock by name or ticker symbol: VNDA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Vanda Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$13.19, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Vanda Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Vanda Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Vanda Pharmaceuticals's share price?

Since the stock market crash in March caused by coronavirus, Vanda Pharmaceuticals's share price has had significant positive movement.

Its last market close was USD$13.19, which is 7.54% up on its pre-crash value of USD$12.195 and 85.25% up on the lowest point reached during the March crash when the shares fell as low as USD$7.12.

If you had bought USD$1,000 worth of Vanda Pharmaceuticals shares at the start of February 2020, those shares would have been worth USD$638.77 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,040.16.

Vanda Pharmaceuticals share price

Use our graph to track the performance of VNDA stocks over time.

Vanda Pharmaceuticals shares at a glance

Information last updated 2020-10-20.
Latest market close USD$13.19
52-week range USD$7.12 - USD$17.75
50-day moving average USD$10.0563
200-day moving average USD$10.9691
Wall St. target price USD$18.33
PE ratio 5.1298
Dividend yield N/A (0%)
Earnings per share (TTM) USD$2.079

Buy Vanda Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Vanguard
$0
Stocks, Mutual funds, ETFs, Forex
$1
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
$0
or $25 broker-assisted
Stocks
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Vanda Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vanda Pharmaceuticals price performance over time

Historical closes compared with the close of $13.19 from 2020-11-16

1 week (2020-11-20) N/A
1 month (2020-10-30) 23.39%
3 months (2020-08-28) N/A
6 months (2020-05-28) N/A
1 year (2019-11-27) N/A
2 years (2018-11-27) N/A
3 years (2017-11-27) N/A
5 years (2015-11-27) N/A

Is Vanda Pharmaceuticals under- or over-valued?

Valuing Vanda Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vanda Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vanda Pharmaceuticals's P/E ratio

Vanda Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 5x. In other words, Vanda Pharmaceuticals shares trade at around 5x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

Vanda Pharmaceuticals's EBITDA

Vanda Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$26.9 million.

The EBITDA is a measure of a Vanda Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Vanda Pharmaceuticals financials

Revenue TTM USD$240.6 million
Operating margin TTM 9.99%
Gross profit TTM USD$202.7 million
Return on assets TTM 3.42%
Return on equity TTM 31.26%
Profit margin 47.31%
Book value $7.9
Market capitalisation USD$564.5 million

TTM: trailing 12 months

Shorting Vanda Pharmaceuticals shares

There are currently 6.0 million Vanda Pharmaceuticals shares held short by investors – that's known as Vanda Pharmaceuticals's "short interest". This figure is 4.2% down from 6.2 million last month.

There are a few different ways that this level of interest in shorting Vanda Pharmaceuticals shares can be evaluated.

Vanda Pharmaceuticals's "short interest ratio" (SIR)

Vanda Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Vanda Pharmaceuticals shares currently shorted divided by the average quantity of Vanda Pharmaceuticals shares traded daily (recently around 726357.97807552). Vanda Pharmaceuticals's SIR currently stands at 8.21. In other words for every 100,000 Vanda Pharmaceuticals shares traded daily on the market, roughly 8210 shares are currently held short.

However Vanda Pharmaceuticals's short interest can also be evaluated against the total number of Vanda Pharmaceuticals shares, or, against the total number of tradable Vanda Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vanda Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Vanda Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1357% of the tradable shares (for every 100,000 tradable Vanda Pharmaceuticals shares, roughly 136 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vanda Pharmaceuticals.

Find out more about how you can short Vanda Pharmaceuticals stock.

Vanda Pharmaceuticals share dividends

We're not expecting Vanda Pharmaceuticals to pay a dividend over the next 12 months.

Vanda Pharmaceuticals share price volatility

Over the last 12 months, Vanda Pharmaceuticals's shares have ranged in value from as little as $7.12 up to $17.75. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vanda Pharmaceuticals's is 0.4688. This would suggest that Vanda Pharmaceuticals's shares are less volatile than average (for this exchange).

Vanda Pharmaceuticals overview

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, and delayed sleep phase disorder; Fanapt® (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; and a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as for the treatment of secretory diarrhea disorders, including cholera. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site